VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
HCA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HCAHCA Healthcare, Inc.
$501.19$108.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksHCACash Flow

HCA Healthcare, Inc. (HCA) Cash Flow Statement

30Y historyFree accessUpdated daily

Operating cash flow of $4.5B in 2026Q3 implied a 2.83x conversion of net income, but quarterly free cash flow margins swung from 3.6% to 16.3% and buybacks of $3.0B consumed most surplus cash, warranting caution about run-rate durability.

Income StatementBalance SheetCash FlowRatios

HCA Cash Flow Statement

Annual statement

HCA Cash Flow Statement

HCA Healthcare, Inc. (HCA) cash flow statement — 30-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations11.17B12.64B10.51B9.43B8.52B8.96B9.23B7.6B6.76B5.43B5.65B4.73B4.45B3.68B4.17B3.93B3.08B2.75B1.8B1.4B1.84B3.16B3.05B2.17B2.75B1.41B1.55B1.22B1.92B1.48B2.62B
Operating CF Margin %-16.71%14.89%14.52%14.15%15.25%17.91%14.81%14.48%12.44%13.63%11.93%12.05%10.77%12.65%12.1%10.05%9.14%6.33%5.2%7.24%12.92%12.97%9.93%13.94%7.87%9.28%7.34%10.26%7.88%13.16%
Operating CF Growth %-29.35%20.18%11.48%10.67%-4.88%-2.96%21.44%12.44%24.6%-4.02%19.41%6.43%20.87%-11.86%6.15%27.49%12.3%52.87%28.72%-24.34%-41.6%3.61%40.77%-21.24%94.62%-8.66%26.49%-36.17%29.2%-43.42%16.28%
Net Income6.78B6.78B6.66B5.24B6.83B7.72B4.39B4.14B4.39B2.74B3.43B2.7B2.37B2B2.01B2.84B1.57B1.38B673M874M1.04B1.42B1.25B1.33B833M886M219M657M532M126M1.5B
Depreciation & Amortization3.74B3.52B3.31B3.08B2.97B2.85B2.72B2.6B2.28B2.13B1.97B1.9B1.82B1.75B1.68B1.47B1.42B1.43B1.42B1.43B1.39B1.37B1.25B1.11B1.01B1.05B1.03B1.09B1.25B1.24B1.16B
Stock-Based Compensation00360M0341M440M362M347M268M270M251M239M163M113M56M26M32M40M32M24M324M0000000000
Deferred Taxes0022M229M571M-70M41M250M74M433M123M-160M-83M143M96M1.71B2.85B169M2.78B1.81B1.44B00000000-163M0
Other Non-Cash Items-404M1.6B269M1.34B-1.04B-1.48B443M352M-281M145M-161M378M439M89M231M842M58M2.83B261M878M591M2.64B3.13B1.86B2.54B1.08B2.03B1.16B1.58B1.92B71M
Working Capital Changes1.06B728M-106M-457M-1.15B-503M1.28B-88M33M-296M42M-323M-264M-414M107M-2.95B-2.85B-3.09B-3.37B-3.62B-2.94B-2.28B-2.58B-2.14B-1.63B-1.6B-1.74B-1.69B-1.45B-1.64B-110M
Change in Receivables-1.07B-94M-799M-935M-797M-962M327M-326M-423M-4.64B-3.25B-4.11B-3.65B-4.39B-3.9B-3.25B-2.79B-3.18B-3.33B00-2.65B000000000
Change in Inventory53M-154M334M-126M-59M-540M-304M-158M-242M-69M-112M-314M-232M-19M-122M-18M-287M-191M159M-241M-12M28M-46M32M-88M-39M90M-119M-39M25M-29M
Change in Payables967M666M359M604M-296M999M1.25B396M698M374M144M192M3.88B4.41B4.02B0000000000000000
Cash from Investing-6.07B-4.99B-4.93B-5.32B-3.39B-2.64B-3.39B-5.72B-3.9B-4.28B-3.24B-2.58B-2.92B-2.35B-2.06B-3B-1.04B-1.03B-1.47B-479M-1.31B-1.68B-1.69B-2.86B-1.74B-1.3B-1.09B925M970M-2.75B-2.25B
Capital Expenditures-5.2B-4.94B-4.88B-4.74B-4.39B-3.58B-2.83B-4.16B-3.57B-3.02B-2.76B-2.38B-2.18B-1.94B-1.86B-1.68B-1.32B-1.32B-1.6B-1.44B-1.86B-1.59B-1.51B-1.84B-1.72B-1.37B-1.16B-1.29B-1.25B-1.42B-1.4B
CapEx % of Revenue6.6%6.54%6.9%7.3%7.3%6.09%5.5%8.1%7.65%6.91%6.65%5.99%5.89%5.68%5.64%5.17%4.32%4.38%5.64%5.38%7.32%6.51%6.44%8.43%8.71%7.63%6.93%7.73%6.72%7.56%7.03%
Acquisitions-779M-128M62M-442M1.01B1.05B-500M-1.62B-445M-1.21B-576M-278M-715M-448M-228M-1.4B-196M-20M108M735M539M194M4M-745M11M280M-23M805M1.84B-411M-816M
Investments-------------------------------
Other Investing-58M12M-120M-131M-7M-121M-58M59M60M-52M96M70M-27M45M27M85M482M-1M25M230M19M-283M-179M-279M-33M-210M91M1.41B674M-1.05B185M
Cash from Financing-5.18B-8.55B-4.58B-4.09B-5.66B-6.66B-4.68B-1.77B-3.08B-1.06B-2.51B-1.98B-1.38B-1.63B-1.78B-976M-1.95B-1.86B-258M-1.16B-240M-1.4B-1.35B650M-934M-342M-336M-2.25B-2.7B1.26B-489M
Debt Issued (Net)5.73B3.21B3.21B1.29B3.29B3.25B-3.22B567M-344M1.51B815M778M778M-692M1.72B-1.59B2.53B-1.53B-260M-1.25B17.59B-106M1.78B1.57B-466M608M922M-535M-2.66B2.38B-423M
Equity Issued (Net)-9.16B-10.07B-6.04B-3.81B-7B-8.21B-441M-1.03B-1.53B-2.05B-2.75B-2.4B-1.75B-500M01B000100M-20.91B-847M-2.88B-949M-15M-1.29B-677M-1.88B8M-1.08B0
Dividends Paid-681M-679M-690M-661M-653M-624M-153M-550M-487M000-7M-16M-3.15B-31M-4.26B000-201M-258M-199M-39M-40M-42M-44M000-54M
Share Repurchases-9.16B-10.07B-6.04B-3.81B-7B-8.21B-441M-1.03B-1.53B-2.05B-2.75B-2.4B-1.75B-500M0-1.5B0000-21.02B-1.86B-3.11B-1.11B-282M-1.51B000-1.08B0
Other Financing-1.07B-1.01B-1.05B-917M-1.29B-1.07B-866M-757M-714M-519M-572M-357M-399M-417M-356M-359M-223M-336M2M-3M3.27B-189M-41M65M-413M385M-537M164M-49M-42M-12M
Net Change in Cash-89M-893M998M27M-543M-342M1.17B119M-230M86M-95M175M152M-291M332M-38M99M-153M72M-241M298M78M14M-46M76M-229M124M-107M187M-3M-119M
Free Cash Flow5.97B7.69B5.64B4.69B4.13B5.38B6.4B3.44B3.19B2.41B2.89B2.36B2.27B1.74B2.31B2.25B1.76B1.43B197M-48M-20M1.57B1.54B328M1.03B43M392M-64M661M61M1.22B
FCF Margin %7.59%10.17%7.99%7.21%6.85%9.16%12.41%6.71%6.83%5.53%6.97%5.95%6.15%5.08%7.01%6.93%5.74%4.76%0.69%-0.18%-0.08%6.41%6.54%1.5%5.23%0.24%2.35%-0.38%3.54%0.32%6.13%
FCF Growth %-26.22%36.41%20.31%13.57%-23.32%-15.87%85.74%8.03%32.23%-16.66%22.64%3.83%30.8%-24.9%2.62%28.07%23.08%625.89%510.42%-140%-101.28%2.02%368.29%-68.22%2300%-89.03%712.5%-109.68%983.61%-95%67.95%
FCF per Share27.5033.3421.5416.9614.0116.3718.529.898.976.487.315.535.043.765.034.544.024.100.56-0.14-0.053.503.180.641.970.080.71-0.101.020.091.80
FCF Conversion (FCF/Net Income)0.88x1.86x1.83x1.80x1.51x1.29x2.46x2.17x1.79x2.45x1.96x2.22x2.37x2.37x2.60x1.60x2.56x2.61x2.67x1.60x1.78x2.22x2.45x1.63x3.30x1.59x5.30x1.65x4.07x-4.86x1.74x
Interest Paid1.08B2.21B1.94B1.89B1.66B1.5B1.61B1.91B1.74B1.7B1.67B1.65B1.76B1.83B1.72B1.99B1.99B1.75B1.98B2.16B893M624M533M00000000
Taxes Paid001.84B1.39B1.18B2.18B1B849M872M1.21B1.25B1.19B1.06B694M618M256M517M1.15B716M421M1.09B563M394M00000000

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Working capital-driven cash volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Operating Cash Flow Outpacing Reported Earnings

According to reported quarterly figures, HCA's operating cash flow ran at roughly 1.0x to 2.8x net income across the ten quarters shown, with the 2026Q3 ratio of 2.83 reflecting unusually strong collections rather than a repeatable earnings base.

The gap between net income and operating cash flow is wide and uneven, which suggests quarterly cash generation is driven heavily by working capital timing rather than steady earnings conversion. Ratios near 1.0x in 2025Q1 and 2026Q1 indicate that when working capital reverses, operating cash flow compresses sharply toward net income. Investors should treat the high-conversion quarters with caution and monitor whether the working capital swings reflect durable collections improvement or temporary timing effects.

Working Capital Swings Drive Cash Volatility

As reported in financial statements, HCA's working capital changes ranged from a $1.7B outflow in 2025Q1 to a $2.3B inflow in 2025Q3, a swing large enough to dominate quarterly operating cash flow.

These alternating inflows and outflows suggest receivables collection and payables timing exert greater influence on reported cash generation than underlying operating profitability. The pattern implies that quarterly free cash flow figures should be read on a trailing-twelve-month basis to avoid misjudging the cash run-rate. Analysts should watch whether the outflow quarters reflect accumulating receivables, which may warrant further investigation into collection efficiency.

Free Cash Flow Margins Remain Highly Uneven

Based on reported figures, HCA's free cash flow margin varied from 3.6% in 2025Q1 to 16.3% in 2025Q2 and 2025Q3, indicating that quarterly FCF is an unreliable single-period indicator for this business.

Averaging the reported quarters suggests a mid-single-digit to high-single-digit normalized FCF margin, which is more informative than any individual period. The trajectory does not show a clear secular trend across the ten quarters, pointing to a business whose cash output depends heavily on timing. Relative to the peer set, HCA's underlying cash margin appears broadly in line with UHS, though the quarterly noise warrants caution.

Capital Intensity Steady at Six to Eight Percent

According to recent SEC filings, HCA's capital expenditures consistently ran between 5.4% and 7.6% of revenue, reflecting the ongoing maintenance and modernization demands of an acute care hospital footprint.

Capex intensity of this magnitude is typical for a hospital operator, and the steady level suggests facility investment is not being cut to inflate free cash flow. Depreciation and amortization of roughly $0.8B to $1.0B per quarter exceeds the reported capex in most periods, which may indicate the asset base is being maintained at a pace that roughly matches wear. Investors should monitor whether capex stays disciplined enough to protect margins in competitive markets.

Buybacks Absorb Surplus Cash Flow

As reported in financial statements, HCA deployed between $1.4B and $3.0B per quarter into share repurchases, consuming most of the free cash flow generated in strong quarters and funding these returns partly through balance sheet capacity.

Repurchases at this pace appear to exceed free cash flow in several quarters, suggesting buybacks are supported by the cash generation in high-conversion periods rather than by steady earnings alone. Dividends of roughly $165M to $183M per quarter are modest by comparison, indicating capital return is weighted toward repurchases. This allocation may enhance per-share metrics but leaves limited cushion if working capital reverses during a period of softer demand.

Headline Cash Strength May Overstate Durability

As reported in financial statements, HCA's strongest quarters, including 2026Q3 with $4.5B operating cash flow, coincide with large working capital inflows, which may indicate that peak cash output is not a reliable run-rate.

Reading the cash flow statement at face value risks mistaking timing benefits for structural improvement, since the quarters with the highest conversion ratios are also those with the largest working capital releases. Stock-based compensation is reported as zero in most periods, so no non-cash equity adjustment is visible in the supplied data, and data is unavailable to assess capitalized costs or off-balance sheet obligations. Investors should warrant further investigation into whether the collection and payables effects reverse in subsequent periods.

HCA — Frequently Asked Questions

Quick answers to the most common questions about buying HCA stock.

How much cash does HCA Healthcare, Inc. (HCA) generate from operations?

HCA Healthcare, Inc. (HCA) generated $12.64B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is HCA Healthcare, Inc.'s free cash flow?

HCA Healthcare, Inc. (HCA) generated $7.69B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is HCA Healthcare, Inc.'s capital expenditure (CapEx)?

HCA Healthcare, Inc. (HCA) spent $4.94B on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does HCA Healthcare, Inc. distribute cash to shareholders?

In 2025, HCA Healthcare, Inc. (HCA) returned $679.0M to shareholders via cash dividends and spent $10.07B on share repurchases. This shows the company's commitment to returning capital to its equity investors.